Evidence map›Paper›PMID 41345253›Full record

ReviewActa pharmacologica Sinica2026

GluD1 at the synaptic crossroads: from domain structure to circuit dysfunction.

Poojashree B Chettiar, Shashank M Dravid

Abstract readReview
In one paragraph

Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Molecular basis for ligand-gating of the human GluD1 receptor.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Poojashree B ChettiarDepartment of Psychiatry and Behavioral Sciences, Naresh K. Vashisht College of Medicine, Texas A&M University, College Station, TX, USA.
Shashank M DravidDepartment of Psychiatry and Behavioral Sciences, Naresh K. Vashisht College of Medicine, Texas A&M University, College Station, TX, USA. smdravid@tamu.edu.ORCID http://orcid.org/0000-0002-9912-8148

Funding

Trans-synaptic signaling complex in amygdala pain mechanismsR01NS118731 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR, NEUGEBAUER, VOLKER · 2020 to 2024
$2.7M
Striatal Trans-Synaptic Signaling Mechanism in ParkinsonismR01NS133338 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Hong-Yuan Chu, Shashank Manohar Dravid · 2024 to 2026
$2.0M
Function of glutamate delta-1 receptorR01MH116003 · NIMH · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR · 2018 to 2022
$1.9M
Structure-Function and Signaling of Glutamate Delta 1 in Pain MechanismR21NS132590 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DRAVID, SHASHANK MANOHAR · 2023 to 2023
$404k
Molecular mechanism of D-cycloserine actionR21MH085327 · NIMH · CREIGHTON UNIVERSITY · PI DRAVID, SHASHANK MANOHAR · 2010 to 2011
$396k
NIMH NIH HHS R01 MH116003NIMH NIH HHS R21 MH085327NINDS NIH HHS R01 NS118731NINDS NIH HHS R01 NS133338NINDS NIH HHS R21 NS132590
6 · The paper itself

Abstract

For several decades, the glutamate delta-1 receptor (GluD1) has remained an enigmatic entity among ionotropic glutamate receptors (iGluRs), primarily due to its lack of classical ion channel activity. Recent advancements have redefined GluD1 as a multifunctional synaptic organizer, essential for the development, plasticity, and behavioral regulation of both excitatory and inhibitory circuits. In this review, we synthesize recent progress at the structural, molecular, and circuit levels to reconceptualize GluD1 as a pivotal signaling scaffold that functions through non-ionotropic mechanisms. We emphasize the modular architecture of GluD1, encompassing the amino-terminal domain, ligand-binding domain, transmembrane region, and C-terminal domain to elucidate how each component uniquely contributes to synaptic function. Evidence from genetic models and structural biology underscores GluD1's involvement in transsynaptic adhesion, ligand-dependent conformational signaling, and intracellular pathway modulation. Additionally, we discuss its emerging clinical significance, with GRID1 mutations associated with neurodevelopmental and psychiatric disorders, and recent findings implicating GluD1 dysfunction in chronic pain. Finally, we explore domain-specific therapeutic strategies, including peptide mimetics, synthetic organizers, and non-ionotropic modulators, positioning GluD1 as a promising target for circuit-level intervention in brain disorders.

Indexed as

Receptors, GlutamateSynapsesAnimalsHumansProtein DomainsSignal Transductionglutamate receptor delta 1Receptors, Glutamateglutamate delta-1 receptor (GluD1)inotropic glutamate receptors (iGluRs)modular receptor domainssynaptic plasticity and organizationtrans-synaptic signaling

Identifiers

PMID41345253
PMCPMC13018601

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.